This white paper outlines five common clinical trial design pitfalls that can undermine regulatory approval, operational success, and commercialization. IQVIA explains how weak development planning, poorly designed studies, operational challenges, regulatory misalignment, and unrepresentative patient populations contribute to costly delays and trial failures. It recommends creating comprehensive development plans, selecting clinically meaningful endpoints, optimizing dose selection, ensuring adequate statistical power, improving operational feasibility, engaging regulators early, and designing trials that reflect real-world patient populations. By integrating scientific, regulatory, and commercial considerations from the outset, sponsors can reduce risk, generate stronger evidence, acceler

Join for free to read